Search Result

Results for "

A ras Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Ras (94) Akt (1) Aminoacyl-tRNA Synthetase (1) Angiotensin Receptor (2) Angiotensin-converting Enzyme (ACE) (2) Apoptosis (19) Autophagy (7) Cyclin G-associated Kinase (GAK) (1) Endogenous Metabolite (4) ERK (8) Farnesyl Transferase (17) Ferroptosis (1) FLT3 (1) Fungal (1) Glutathione Peroxidase (1) HDAC (2) HIF/HIF Prolyl-Hydroxylase (1) ICMT (5) MAGL (1) MAPKAPK2 (MK2) (1) MEK (3) MMP (1) Molecular Glues (1) NOD-like Receptor (NLR) (1) Phosphatase (1) Phosphodiesterase (PDE) (2) Phospholipase (2) PI3K (1) PROTACs (3) Raf (8) RET (1) ROR (1) SHP2 (3) Tyrosinase (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (132) Cardiovascular Disease (2) Endocrinology (2) Infection (6) Inflammation/Immunology (9) Neurological Disease (1)
Click Chemistry:	Alkynes (2)

141

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Click Chemistry

Targets Recommended: Ras

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14754

Salirasib 5+ Cited Publications S-Farnesylthiosalicylic acid; Farnesyl Thiosalicylic Acid; FTS	Ras Autophagy	Cancer
Salirasib is a *Ras* inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.

HY-138294

RAS/RAS-RAF-IN-1 1 Publications Verification	Ras Raf	Cancer
RAS/RAS-RAF-IN-1 is a potent *RAS* and *RAS-RAF* inhibitor. RAS/RAS-RAF-IN-1 has a K_D of 5.0 μΜ-15 μΜ for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity .

HY-101295

Pan-RAS-IN-1

5 Publications Verification

Ras Cancer

Pan-RAS-IN-1 is a pan-Ras inhibitor that disrupts the interaction of Ras proteins and their effectors.

Pan-RAS-IN-1 5 Publications Verification	Ras	Cancer
Pan-RAS-IN-1 is a *pan-Ras* inhibitor that disrupts the interaction of Ras proteins and their effectors.

HY-122862

*RAS inhibitor* Abd-7** 1 Publications Verification	Ras	Cancer
RAS inhibitor Abd-7, a potent RAS-binding compound (K_d=51 nM), is a RAS-effector protein-protein interaction (PPI) inhibitor. RAS inhibitor Abd-7 interacts with RAS inside the cells, prevents RAS-effector interactions and inhibits endogenous RAS-dependent signaling. RAS inhibitor Abd-7 impairs the PPI of various mutant KRAS proteins with PI3K, CRAF and RALGDS as well as NRAS Q61H and HRAS G12V .

HY-18674

K-Ras-IN-1	Ras	Cancer
K-Ras-IN-1 is a *K-Ras* inhibitor. K-Ras-IN-1 binds K-Ras (WT), K-Ras (G12D), K-Ras (G12V), and H-Ras. K-Ras-IN-1 has the potential to be used in research on pancreatic, colon and lung cancer .

HY-12446

K-Ras(G12C) inhibitor 9

Ras Cancer

K-Ras (G12C) inhibitor 9 is an allosteric inhibitor of the K-Ras (G12C) .

*K-Ras(G12C) inhibitor* 9**	Ras	Cancer
K-Ras (G12C) inhibitor 9 is an allosteric inhibitor of the K-Ras (G12C) .

HY-19539

NSC-658497
NSC-658497 is an effective inhibitor of Ras-GEF, SOS1. NSC-658497 binds to SOS1, competitively suppresses SOS1-Ras interaction, and dose-dependently inhibits SOS1 GEF activity. NSC-658497 showed dose-dependent efficacy in inhibiting Ras, downstream signaling activities, and associated cell proliferation .

HY-18707

K-Ras(G12C) inhibitor 12

Ras Apoptosis Cancer

K-Ras(G12C) inhibitor 12 is a K-Ras(G12C) inhibitor. K-Ras(G12C) inhibitor 12 acts on H1792 cells with an EC50 of 0.32 μM.

*K-Ras(G12C) inhibitor* 12**	Ras Apoptosis	Cancer
K-Ras(G12C) inhibitor 12 is a K-Ras(G12C) inhibitor. K-Ras(G12C) inhibitor 12 acts on H1792 cells with an EC50 of 0.32 μM.

HY-15879

LB42708	Farnesyl Transferase Apoptosis	Inflammation/Immunology
LB42708 is a potent, selective and orally active farnesyltransferase inhibitor. LB42708 inhibits farnesylation of *H-Ras, N-Ras* and *K-Ras4B* with IC₅₀s of 0.8 nM, 1.2 nM and 2.0 nM, respectively .

HY-107841

K-Ras(G12C) inhibitor 6

Ras Cancer

K-Ras(G12C) inhibitor 6 is an irreversible, allosteric inhibitor of the K-Ras(G12C) .
HY-18605

K-Ras G12C-IN-2

Ras Cancer

K-Ras G12C-IN-2 is an irreversible covalent K-Ras G12C inhibitor.

*K-Ras(G12C) inhibitor* 6**	Ras	Cancer
K-Ras(G12C) inhibitor 6 is an irreversible, allosteric inhibitor of the *K-Ras(G12C)* .

K-Ras G12C-IN-2	Ras	Cancer
K-Ras G12C-IN-2 is an irreversible covalent *K-Ras* G12C** inhibitor.

HY-107753

XRP44X	Ras	Inflammation/Immunology Cancer
XRP44X inhibits *Ras*-induced transcription activation with the IC₅₀ of 10 nM. XRP44X inhibits activation of the Ras-Erk-1/2 pathway by FGF-2 . XRP44X is an inhibitor of Ras/Erk activation of Elk3 that also affects microtubules .

HY-18606

K-Ras G12C-IN-3

Ras Cancer

K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.

K-Ras G12C-IN-3	Ras	Cancer
K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.

HY-15136

Lonafarnib 5+ Cited Publications Sch66336	Farnesyl Transferase Ras Autophagy	Infection Cancer
Lonafarnib (Sch66336) is a potent and orally active farnesyl transferase (FTase) inhibitor. Lonafarnib inhibits the activities of *H-ras, K-ras* and *N-ras* with IC₅₀ values of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Lonafarnib also has anti-hepatitis delta virus (HDV) activities.

HY-15716

Kobe0065 3 Publications Verification	Ras Apoptosis	Cancer
Kobe0065 is a novel and effective inhibitor of Ras-Raf interaction, competitively inhibiting the binding of H-Ras·GTP to c-Raf-1 RBD with a K_i value of 46±13 μM.

HY-115555

K-Ras-PDEδ-IN-1	Phosphodiesterase (PDE)	Cancer
K-Ras-PDEδ-IN-1 is a novel and potent competitive *K-Ras-PDEδ* inhibitor. K-Ras-PDEδ-IN-1 binds to the farnesyl binding pocket of PDEδ with a low nanomolar K_d of 8 nM .

HY-129189

*RAS GTPase inhibitor* 1**	Ras	Cancer
RAS GTPase inhibitor 1 (example 51) is a RAS GTPase inhibitor with anti-tumor activity, extracted from patent WO2018212774A1. RAS GTPase inhibitor 1 (example 51) exhibits an EC₅₀ less than 1 μM for at least one nucleotide exchange and an IC₅₀ less than 1 μM in H727 cells .

HY-15136B

(Rac)-Lonafarnib Sch66336 racemate	Farnesyl Transferase	Infection Cancer
(Rac)-Lonafarnib (Sch66336 racemate) is the racemate of Lonafarnib. Lonafarnib is a potent and orally active farnesyl transferase (FTase) inhibitor. Lonafarnib inhibits the activities of *H-ras, K-ras* and *N-ras* with IC₅₀ values of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Lonafarnib also has anti-hepatitis delta virus (HDV) activities .

HY-157887

ADT-007	Ras	Cancer
ADT-007 is a potent and orally active pan-RAS inhibitor with strong anticancer effects. ADT-007 binds RAS in a nucleotide-free conformation to block GTP activation. ADT-007 potently and selectively inhibits the growth of cancer cells with mutated or hyper-activated wild-type RAS isozymes .

HY-128044

*Ftase inhibitor* I** B581	Farnesyl Transferase	Cancer
Ftase inhibitor I (B581) is a potent, selective and peptidomimetic farnesyl transferase (FTase) inhibitor. Ftase inhibitor I shows selectivity for FTase over geranylgeranyl isoprenoid (Ras-GG) or the fatty acid myristate (Myr-Ras) .

HY-15717

Kobe2602

Ras Cancer

Kobe2602 is a Ras-Raf interaction inhibitor. Kobe2602 inhibits the binding of H-Ras·GTP to c-Raf-1 RBD with a K_i of 149 μM. Kobe2602 has antitumor activity .
HY-P3277

KRpep-2d

Ras Cancer

KRpep-2d is a potent K-Ras inhibitor and inhibits proliferation of K-Ras-driven cancer cells. KRpep-2d can be used for cancer research .

Kobe2602	Ras	Cancer
Kobe2602 is a Ras-Raf interaction inhibitor. Kobe2602 inhibits the binding of H-Ras·GTP to c-Raf-1 RBD with a K_i of 149 μM. Kobe2602 has antitumor activity .

KRpep-2d	Ras	Cancer
KRpep-2d is a potent *K-Ras* inhibitor and inhibits proliferation of K-Ras-driven cancer cells. KRpep-2d can be used for cancer research .

HY-124514

UC-857993	Ras ERK	Cancer
UC-857993 is a selective *SOS1-Ras* inhibitor (K_d=14.7 μM, His₆-SOS1_cat), suppressing catalytic activity. UC-857993 also inhibits ERK and *Ras* activation, suppresses the growth of mouse embryonic fibroblasts (MEFs) .

HY-P3277A

KRpep-2d TFA

Ras Cancer

KRpep-2d (TFA) is a potent K-Ras inhibitor and inhibits proliferation of K-Ras-driven cancer cells. KRpep-2d can be used for cancer research .
HY-139950

Rasarfin

Ras Cancer

Rasarfin is a dual Ras and ARF6 inhibitor .
HY-18604

K-Ras G12C-IN-1

Ras Cancer

K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C extracted from patent WO 2014152588 A1.

KRpep-2d TFA	Ras	Cancer
KRpep-2d (TFA) is a potent *K-Ras* inhibitor and inhibits proliferation of K-Ras-driven cancer cells. KRpep-2d can be used for cancer research .

Rasarfin	Ras	Cancer
Rasarfin is a dual *Ras* and ARF6 inhibitor .

K-Ras G12C-IN-1	Ras	Cancer
K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C extracted from patent WO 2014152588 A1.

HY-123673

MCP110 1 Publications Verification	Ras Raf	Cancer
MCP110 is an inhibitor of *Ras/Raf-1* interaction. MCP110 blocks the interaction of Ras with Raf. MCP110 disrupts this interaction might can be used for the research of human tumors .

HY-155954

UCM-1336	Apoptosis Autophagy	Cancer
UCM-1336 is a potent ICMT inhibitor, with an IC₅₀ of 2 μM. UCM-1336 induces mislocalization of endogenous Ras, decreases Ras activation and induces cell death by autophagy and apoptosis .

HY-15872

FTI-277	Farnesyl Transferase Apoptosis Ras	Infection Cancer
FTI-277 is an inhibitor of farnesyl transferase (FTase); a highly potent Ras CAAX peptidomimetic which antagonizes both H- and *K-Ras* oncogenic signaling*. FTI-277 can inhibit* hepatitis delta virus (HDV) infection.

HY-15872A

FTI-277 hydrochloride 3 Publications Verification	Farnesyl Transferase Apoptosis Ras	Infection Cancer
FTI-277 hydrochloride is an inhibitor of farnesyl transferase (FTase); a highly potent Ras CAAX peptidomimetic which antagonizes both H- and *K-Ras* oncogenic signaling*. FTI-277 hydrochloride can inhibit* hepatitis delta virus (HDV) infection.

HY-149710

POP-3MB	ICMT ERK	Cancer
POP-3MB (compound 1b) is an ICMT inhibitor (IC₅₀: 2.5 μM). POP-3MB changes the subcellular localization of K-Ras and inhibits Ras activation. POP-3MB also inhibits Erk phosphorylation .

HY-134885

RMC-0331 1 Publications Verification RM-023	SHP2 Ras	Cancer
RMC-0331 (RM-023) is a potent, selective and orally bioavailable SOS1 inhibitor. RMC-0331 is an in vivo tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction .

HY-N6674

Diazepinomicin ECO-4601; TLN-4601; BU 4664L	Ras Apoptosis	Cancer
Diazepinomicin (TLN-4601) is a secondary metabolite produced by Micromonospora sp. Diazepinomicin (TLN-4601) inhibits the EGF-induced Ras-ERK MAPK signaling pathway and induces apoptosis. An anti-tumor agent for K-Ras mutant models .

HY-150926

G12Si-1	Ras	Cancer
G12Si-1 is a selective *K-Ras(G12S)* covalent inhibitor, which can inhibit oncogenic signaling of *K-Ras(G12S). G12Si-1 shows good ability to covalently engage recombinant K-Ras(G12S)* at the mutant serine residue. G12Si-1 can also affect nucleotide cycling of K-Ras by blocking Sos-catalyzed exchange and decreasing the rate of EDTA promoted exchange .

HY-14947

Balamapimod

MKI 833
MEK Cancer

Balamapimod (MKI 833) is a reversible Ras/Raf/MEK inhibitor with potential anti-tumor activity.
HY-124161

SCH54292

Ras Cancer

SCH54292 is a potent Ras-GEF interaction inhibitor with IC₅₀ of 0.7 μM .
HY-153488

ISIS 2503

Ras Cancer

ISIS-2503 is a 20-mer antisense oligonucleotide that inhibits Ha-Ras expression
HY-153488A

ISIS 2503 sodium

Ras Cancer

ISIS-2503 sodium is a 20-mer antisense oligonucleotide that inhibits Ha-Ras expression

Balamapimod MKI 833	MEK	Cancer
Balamapimod (MKI 833) is a reversible *Ras/Raf/MEK* inhibitor with potential anti-tumor activity.

SCH54292	Ras	Cancer
SCH54292 is a potent *Ras-GEF* interaction inhibitor with IC₅₀ of 0.7 μM .

ISIS 2503	Ras	Cancer
ISIS-2503 is a 20-mer antisense oligonucleotide that inhibits Ha-Ras expression

ISIS 2503 sodium	Ras	Cancer
ISIS-2503 sodium is a 20-mer antisense oligonucleotide that inhibits *Ha-Ras* expression

HY-156500

ICMT-IN-1	ICMT	Cancer
ICMT-IN-1 (compound 75) is an inhibitor of ICMT (IC₅₀=0.0013 μM). ICMT-IN-1 dose-dependently induces ICMT accumulation in the cytoplasm of HCT-116 cells and inhibits the proliferation of multiple cancer cell lines expressing K-Ras and N-Ras .

HY-149705

ICMT-IN-7	ICMT	Cancer
ICMT-IN-7 (compound 74) is an inhibitor of ICMT (IC₅₀=0.015 μM). ICMT-IN-7 dose-dependently induces ICMT accumulation in the cytoplasm of HCT-116 cells and inhibits the proliferation of multiple cancer cell lines expressing K-Ras and N-Ras .

HY-13452

CID-1067700 5+ Cited Publications ML282	Ras	Inflammation/Immunology
CID-1067700 (ML282) is a pan GTPase inhibitor, and competitively inhibits Ras-related in brain 7 (Rab7) with a K_i of 13 nM.

HY-12408

6H05

Ras Cancer

6H05 is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C).
HY-12656

SCH 51344

Ras Cancer

SCH 51344 inhibits Ras induced malignant transformation and prevents anchorage-independent growth of oncogene transformed fibroblasts .
HY-148439

RMC-6236

ras-IN-2
Ras Cancer

RMC-6236 (Compound A122) is a potent RAS(ON) ^MULTI inhibitor and can be used for the research of cancer .

6H05	Ras	Cancer
6H05 is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C).

SCH 51344	Ras	Cancer
SCH 51344 inhibits Ras induced malignant transformation and prevents anchorage-independent growth of oncogene transformed fibroblasts .

RMC-6236 ras-IN-2	Ras	Cancer
RMC-6236 (Compound A122) is a potent RAS(ON) ^MULTI inhibitor and can be used for the research of cancer .

HY-114398

BAY-293 1 Publications Verification	Ras	Cancer
BAY-293, a valuable chemical probe, blocks *RAS* activation via disruption of the KRAS-SOS1 interaction with an IC₅₀ of 21 nM. BAY-293 is a potent inhibitor of Son of Sevenless 1 (SOS1). SOS1 is the guanine nucleotide exchange factor (GEF) and activator of RAS .

HY-114569

6-CEPN	Ras Cyclin G-associated Kinase (GAK) Autophagy	Cancer
6-CEPN is a *RAS* inhibitor. 6-CEPN can inhibit *RAS* activation by binding to Icmt binding sites. 6-CEPN has anticancer activity. 6-CEPN can block cancer cells in the G1 phase. 6-CEPN can induce autophagy and necrosis of Cancer cells (Icmt: isovalerylcysteine carboxymethyltransferase) .

HY-12408A

6H05 TFA

Ras Cancer

6H05 TFA is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C).
HY-129273

L-731735

Farnesyl Transferase Cancer

L-731735 is a selective FPTase inhibitor that can inhibit ras-dependent cell transformation. L-731735 can be used in cancer research .

HY-156498

RMC-7977	Ras	Cancer
RMC-7977 is a reversible, tri-complex RAS inhibitor with broad spectrum activity for both mutant and wild-type (WT) KRAS, NRAS, and HRAS variants.RMC-7977 can lead to tumor regressions and was well tolerated in diverse RAS-addicted preclinical cancer models. RMC-7977 also can inhibit the growth of KRAS ^G12C cancer models .

HY-18997

PLX7904

3 Publications Verification

PB04
Raf Cancer

PLX7904 is a potent and selective BRAF inhibitor, with IC₅₀ of appr 5 nM against BRAF ^V600E in mutant RAS expressing cells.

Cat. No.	Product Name	Target	Research Area

HY-P3277

KRpep-2d

Ras Cancer

KRpep-2d is a potent K-Ras inhibitor and inhibits proliferation of K-Ras-driven cancer cells. KRpep-2d can be used for cancer research .
HY-P3277A

KRpep-2d TFA

Ras Cancer

KRpep-2d (TFA) is a potent K-Ras inhibitor and inhibits proliferation of K-Ras-driven cancer cells. KRpep-2d can be used for cancer research .

HY-12403A

Talfirastide acetate 5+ Cited Publications TXA127 acetate; Angiotensin (1-7) (acetate); Ang-(1-7) (acetate)	Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology Endocrinology
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC₅₀=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .

HY-12403

Talfirastide 5+ Cited Publications TXA127; Angiotensin (1-7); Ang-(1-7)	Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology Endocrinology
Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC₅₀=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .

HY-P10051

Cyclorasin 9A5

Ras Raf Cancer

Cyclorasin 9A5 is an 11-residue cell-permeable cyclic peptide that orthosterically inhibits the Ras-Raf protein interaction with an IC₅₀ of 120 nM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

A ras Inhibitors

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

NaturalProducts

Click Chemistry

Natural
Products